Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.18081
Abstract: Atractylodes macrocephala III (ATL III), with anti‐inflammatory and antitumor effects, is the main compound of Atractylodes macrocephala. Whether ATL III has an effect on cervical cancer and the specific mechanism are still unclear. Here, we… read more here.
Keywords: cancer; cancer cells; atractylodes macrocephala; atl iii ... See more keywords
Atractylenolide III inhibits epithelial-mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2022.12614
Abstract: Compared with the available drugs for the treatment of fibrosis in other organs, the development of intestinal anti-fibrosis drugs is limited. Therefore, it is of practical significance to examine novel drugs to delay or block… read more here.
Keywords: mesenchymal transition; atl iii; atractylenolide iii; iii ... See more keywords
Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.68873
Abstract: Background: Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver diseases worldwide. At present, there are no effective pharmacological therapies for NAFLD except lifestyle intervention-mediated weight loss. Atractylenolide III (ATL III),… read more here.
Keywords: atl iii; treatment; adiponectin receptor; fatty liver ... See more keywords